D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
Abstract
PD-L1 is well known as an immune checkpoint molecule, which suppresses immune surveillance through binding to its receptor PD-1. Intracellular PD-L1 can also protect messenger RNAs of several DNA damage repair-related genes from degradation and enhance tumor resistance to DNA-damaging therapy. Triple-negative breast cancer (TNBC) has the worst prognosis and highest risk of distant relapse in breast cancer and shows resistance to immunotherapy and radiotherapy. In this study, we found that D-mannose can promote the degradation of PD-L1 and significantly enhance immunotherapy and radiotherapy of TNBC. Since TNBC treatment is still a clinical challenge, our findings provide strategies to enhance the therapeutic efficacy of TNBC and may have clinical application.
- Publication:
-
Proceedings of the National Academy of Science
- Pub Date:
- February 2022
- DOI:
- 10.1073/pnas.2114851119
- Bibcode:
- 2022PNAS..11914851Z